I've finally published a long-gestating piece about why India has largely failed at research & development, and inventing novel products downstream of R&D, over the past few decades, as well as what we can do about it.
www.infinitesunrise.com/p/overcoming...
It is indeed striking how much AF3-based methods struggle to generalize to novel protein-ligand interfaces. It is also interesting that there remains a meaningful delta between AF3 and other reproductions at the most difficult generalization task (~25% vs ~13% success rate, so roughly double).
It's long seemed that molecular biology is a natural home for ML interpretability research, given the maturity of human-constructed models of biological mechanisms—permitting direct comparison with their ML-derived counterparts—unlike vision and NLP. Our first foray below👇.
I presented on PopVax’s ongoing efforts to develop broadly-protective mRNA vaccines against influenza and other pathogens at the BARDA Vaccine Innovation Forum held on January 13 in San Francisco. Here’s BARDA’s press release about the prize: (11/12)
www.medicalcountermeasures.gov/newsroom/202...
We believe broadly-protective flu vaccines are vital to save lives each flu season and prevent potential future pandemics. This work would not have been possible without generous support for our vaccine platform and open-source COVID-19 vaccine from Vitalik Buterin (@vitalik.ca) & Balvi. (10/12)
We are also developing vaccines that cover potential pandemic strains such as H5N1, which appears to already be undergoing mutations that may allow it to replicate more easily in mammalian cells, creating an increased risk of transmission to and between humans. (9/12)
Current seasonal flu vaccines can often be ineffective – in the past decade, their efficacy in a given flu season has fallen to as low as 6% due to strain mutation. PopVax is developing broadly-protective flu vaccines intended to reliably provide 80%+ efficacy. (8/12)
Formulation into a microarray patch also enhances mRNA vaccine thermostability, broadening global accessibility. PopVax & LTS are working to advance the self-administered patch-delivered seasonal influenza vaccine into preclinical studies in the coming months. (7/12)
Imagine getting a vaccine delivered to your home on demand via DoorDash or Zomato, and administering it yourself by applying a small patch to your upper arm that can be discarded in 15 minutes – no need to go to a pharmacy or clinic and wait in line to be injected. (6/12)
We are working with Germany’s LTS Lohmann Therapie-Systeme AG, a leading player in transdermal drug delivery, to deliver our flu vaccine using their self-administrable microarray patch delivery system. (5/12)
The vaccine is built on our mRNA-encoded immunogen display architecture that boosts the magnitude and breadth of the elicited strain-specific antibody response, and our lipid nanoparticle (LNP) platform built on PopVax-designed novel ionizable lipids. (4/12)
Our influenza vaccine candidate shows as much as 250x greater strain-specific antibody response in mice in comparison with a leading approved influenza vaccine. It also elicits a broader antibody response, including against pandemic H5N1 influenza, a rising threat. (3/12)
The Patch Forward Prize is a multi-stage $50M competition launched by BARDA to accelerate the development of microneedle patch-based RNA vaccines for COVID-19, seasonal influenza, and pandemic influenza. (2/12)
I'm delighted to announce that PopVax (@popvax.com) has been awarded $2M by the US Biomedical Advanced Research and Development Authority (@bardagov.bsky.social) as a winner of the first stage of BARDA’s Patch Forward Prize for our seasonal influenza vaccine, along with our partner LTS. (1/12)
Rare bird flu strain #H5N9 found in California flock infected with #H5N1, reports @washingtonpost.com.
"Culling flocks is costly," says @jennifernuzzo.bsky.social . "We see that in the price of eggs, and the continued infection of cows will only add to the economic burden."
Read more ⤵️
So here's an interesting development...
It's been observed that shingles vaccination with the live attenuated vaccine Zostavax:
www.medrxiv.org/content/10.1...
and also with the (much more effective) recombinant vaccine:
www.nature.com/articles/s41...
But, though the study designs are strong...
You can read more of what I’ve written about the emergence of H5N1 and the utility of vaccines that elicit a broader immune response here:
chronicles.popvax.com/p/potent-bro...
We are eager to work with investors, industry partners, governments, and regulators to accelerate the development and clinical testing of our influenza vaccines. If this is of interest to you, please reach out to us via email at flu25@popvax.com.
We also have an H5N1 influenza vaccine candidate that elicits robust antibody responses against both the same strain of H5N1 that it is based on as well as other distinct H5N1 strains in mice.
A vaccine such as ours could be used primarily as a seasonal influenza vaccine of the kind that hundreds of millions of people take each year, but has the potential to additionally provide some protection against H5N1 and other emerging strains which current influenza vaccines do not.
Our vaccine candidate also elicits as much as 250x greater antibody response in mice against seasonal strains compared with a seasonal influenza vaccine from the global market leader.
At PopVax (@popvax.com) we’ve been developing broadly-protective vaccines against influenza, and are already seeing signs of potential utility against H5N1. Our seasonal influenza candidate elicits a potent antibody response against H5N1 despite not containing an H5N1 antigen.
While we all certainly hope that H5N1 influenza doesn’t mutate into a strain that causes a pandemic in humans, there is a distinct and unnerving possibility that it does, as Alex Tabarrok (marginalrevolution.com/marginalrevo...) and commentary in @nejm.org have recently noted.
I've written a short piece about the potent, broadly-protective flu vaccines we're developing at PopVax to protect against both seasonal influenza strains and potential pandemic influenza such as the H5N1 strains currently circulating in cows
chronicles.popvax.com/p/potent-bro...
(thread below)
I'm co-hosting the first Builders in Biology meetup with Samarth Jajoo in Hyderabad on Jan 7 at the @popvax.com lab. It's an informal gathering to discuss research ideas people are excited about. Please feel free to register here if you're interested: lu.ma/po606g0h
We now seek to apply our v/acc approach – vaccine accelerationism – to HCV, Strep A, and TB, three pathogens which collectively kill ~2 million people a year, and for which there are no existing effective vaccines. More in the video below: (4/4)
youtu.be/OXxo49WrODQ
Our soon-to-be open sourced COVID-19 vaccine funded by Vitalik & Balvi is designed to protect against both current & future variants of SARS-CoV-2, aligning with the goals of d/acc. It will enter a Phase I trial in the US conducted & sponsored by NIAID (@niaidnews.bsky.social) in 2025. (3/4)
Vitalik, via his biosecurity and public health organization Balvi, was the first to believe in our vision of leveraging the 10x cost & speed advantages of doing R&D in India to develop fundamentally better, broader, safer, and more transparent vaccines, and is our largest funder. (2/4)
I recently spoke at Ethereum Devcon about PopVax (@popvax.com)'s work developing novel mRNA vaccines to save 1 million lives each year, as part of a series of talks organized by Vitalik Buterin (@vitalik.ca) around his d/acc vision – defensive, differential, and decentralized accelerationism. (1/4)
